Aegis Capital Affirms Sinovac (SVA) at 'Buy'; Sees Revenue from EV71 Potentially in FY14
Tweet Send to a Friend
Aegis Capital maintains its Buy rating and $7 price target on Sinovac Biotech (Nasdaq: SVA) following quarterly results reported earlier ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
